Cardiac_toxicity_4_to_20_years_after_completing_anthracycline_therapy._OBJECTIVE.--To_assess_the_cardiac_status_of_long-term_survivors_of_pediatric_malignancies_who_received_chemotherapy,_including_anthracyclines._DESIGN_AND_METHOD.-Patients_were_evaluated_by_echocardiogram_from_4_to_20_years_(median,_7_years)_after_completion_of_anthracyclines,_with_prospective_and_retrospective_analysis._PATIENTS.--The_consecutive_sample_of_201_patients_had_received_a_total_anthracycline_dose_of_200_to_1275_mg/m2_(median,_450_mg/m2),_and_51_patients_had_mediastinal_radiotherapy._MAIN_OUTCOME_MEASURES.--The_overall_incidence_and_severity_of_abnormal_systolic_cardiac_function_were_determined_for_the_entire_cohort._Risk_factors_of_total_anthracycline_dose,_mediastinal_radiotherapy,_age_during_treatment,_and_length_of_follow-up_were_examined._RESULTS.--Twenty-three_percent_(47/201)_of_the_cohort_had_abnormal_cardiac_function_on_noninvasive_testing_at_long-term_follow-up._Correlation_between_total_cumulative_dose,_length_of_follow-up,_and_mediastinal_irradiation_with_incidence_of_abnormalities_was_significant._Fifty-six_patients_were_followed_up_for_10_years_or_more_(median,_12_years),_with_a_median_anthracycline_dose_of_495_mg/m2._Thirty-eight_percent_(21/56)_of_these_patients,_compared_with_18%_(26/145)_of_patients_evaluated_after_less_than_10_years,_had_abnormal_findings._Sixty-three_percent_of_patients_followed_up_for_10_years_or_more_after_receiving_500_mg/m2_or_more_of_anthracyclines_had_abnormal_findings._Nine_of_201_patients_had_late_symptoms,_including_cardiac_failure_and_dysrhythmia,_and_three_patients_died_suddenly._Microscopic_examination_of_the_myocardium_on_biopsy_and_autopsy_revealed_fibrosis._CONCLUSION.--The_23%_incidence_of_late_cardiac_abnormalities_warrants_continued_evaluation_of_patients_after_anthracyclines_to_guide_patient_care_and_the_design_of_future_chemotherapeutic_protocols.